Cannabis-derived THC shows promise for treating PTSD-related nightmares
Drastic or even life-threatening events can have lingering effects, like an echo. This is referred to as post-traumatic stress disorder (PTSD). The brain is unable to process these overwhelming experiences and stores the memories in such a way that they cannot be consciously controlled. They resurface again and again, including at night, when people with PTSD relive the trauma over and over until…
A new study published in Nature Medicine reveals that cannabis-derived THC may offer a promising treatment for PTSD-related nightmares. Post-traumatic stress disorder (PTSD) affects individuals who have experienced drastic or life-threatening events, causing them to relive the trauma in nightmares at night. Current treatments, such as antidepressants and blood pressure-lowering medications, only provide partial relief and do not specifically target nightmares.
Previous research has shown that THC, the psychoactive compound found in cannabis, interacts with the body's endocannabinoid system and can reduce dream activity during REM sleep, potentially alleviating stress responses.
In this study, researchers from Charité, a medical university in Germany, conducted a 10-week randomized controlled trial involving over 170 patients with PTSD and frequent, intense nightmares. The participants either received the prescription medication dronabinol, a form of THC derived directly from the cannabis plant, or an identical-looking cannabis-flavored placebo every evening before bedtime.
Neither the healthcare providers nor the participants knew who received which treatment, ensuring the study's validity through a double-blind, placebo-controlled design.
The results showed that nightmare burden decreased significantly more in the dronabinol group compared to the placebo group. On a scale of 0 to 8 points, nightmare burden decreased by an average of 3.7 points in the dronabinol group, compared with only 2.2 points in the placebo group. More than a third of the participants treated with dronabinol reported that they no longer experienced any nightmares after 10 weeks, and another 21% reported that their nightmare burden had been at least halved.
Additionally, about five out of six patients in the dronabinol group reported that their overall health had markedly improved.
While the study found that dronabinol had a specific effect on nightmares and sleep, it did not significantly affect the severity of PTSD symptoms or depression. The majority of participants experienced significant relief from nightmares, allowing for restful sleep. Mild-to-moderate side effects such as dizziness, headache, and increased appetite were observed but were considered relatively mild compared to the significant improvement in nightmares.
Importantly, no severe side effects or withdrawal symptoms were observed after the study period. The researchers plan to investigate the long-term effectiveness and safety of dronabinol treatment for PTSD-related nightmares in future studies.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
